1.
|
Phase: Phase IV
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CZOL446EAU22, NCT00434447
|
|
2.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 14556, AC0910CZ, ANES, NCT00919022
|
|
3.
|
Phase: Phase III, Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 001-0015-211, NCT00127387
|
|
4.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: MRC-STAMPEDE, EU-205102, MRC-PR08, ISRCTN78818544, EUDRACT-2004-000193-31, NCT00268476
|
|
5.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HEC/WST0512 66N/WST 2.21, NCT00312442
|
|
6.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 79
Sponsor: Pharmaceutical / Industry
Protocol IDs: AMT/P2CA/001, LC003AURON2005, NCT00332280
|
|
7.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 45 to 80
Sponsor: Other
Protocol IDs: CURC/CUOG-AVIAS-0601, NCT00553878
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Adult
Sponsor: NCI
Protocol IDs: SWOG-9346, SWOG-9346, CAN-NCIC-PR8, CALGB-9594, ECOG-S9346, EORTC-30985, CAN-NCIC-JPR8, INT-0162, NCT00002651, PR8
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: MDA-ID-00156, NCI-3410, 3410, NCT00024167
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CALGB-90202, ECOG-CALGB-90202, NCT00079001, SWOG-CALGB-90202, CAN-NCIC-PRC2
|
|
11.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: PMCC-VCOG-PR-0103, PMCC-TROG-0306, NCT00110162
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: SWOG-S0421, S0421, NCT00134056
|
|
13.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: AVENTIS-FIN-1-2003, FINNISH-URO-OGS-1-2003, PROSTY-FIN-1-2003, NCT00255606
|
|
14.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E3805, E3805, NCT00309985
|
|
15.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: ROLL-GUP-0205-1, UCLA-0507059-01, NCT00336934
|
|
16.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2005242-01H, OTT 05-02, NCT00326638
|
|
17.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N0574, N0574, ACOSOG-N0574, NCT00377156
|
|
18.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: FRE-FNCLCC-GETUG-16/0504, EU-20668, EUDRACT-2005-005165, NCT00423475
|
|
19.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: CSET 1248, IGRT-P, NCT00433706
|
|
20.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Any age
Sponsor: Pharmaceutical / Industry
Protocol IDs: DOCET_L_01833, NCT00436839
|
|
21.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: OCOG-P1, NCT00439751
|
|
22.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006-002948-28, KKS-73-05, NCT00444093
|
|
23.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XRP6976J_3503, EudraCT#:2007-000323-17, NCT00514917
|
|
24.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EFC6546, EUDRACT : 2006-004756-20, NCT00519285
|
|
25.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D4320C00033, NCT00617669
|
